Related Experiment Video
Updated: Aug 15, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
Multiple sclerosis and related disorders: Short report peripheral vascular events in a real-world cohort of multiple
Carolina Pelayo1, Ethel Ciampi2, Reinaldo Uribe-San-Martín2
1Neurology Department, Pontificia Universidad Católica de Chile, Chile.
Background:
Fingolimod is a high-efficacy disease-modifying therapy for multiple sclerosis (MS) and was the first oral treatment approved for the disease. Adverse events include bradyarrhythmia, hypertension, macular oedema and increased risk of infections, mainly due to its main mechanism of action, the non-selective modulation of sphingosine-1-phosphate receptor.
Methods And Results:
We report the baseline characteristics, effectiveness outcomes and adverse events of a prospective cohort of 177 patients with a median treatment duration of 24 months, in which four patients (2.3%) presented with otherwise non-provoked peripheral vascular events (PVE).
Conclusions:
Further studies are still needed to evaluate the frequency and severity of PVE in fingolimod patients.
Related Concept Videos
Peripheral Artery Disease I: Introduction
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease IV: Nursing Management
Multiple Sclerosis l: Introduction

